Second-generation antipsychotic drugs and extrapyramidal side effects: A systematic review and meta-analysis of head-to-head comparisons

Schizophrenia Bulletin

Volumn 38, Issue 1, 2012, Pages 167-177

  Rummel Kluge, Christine ^a   Komossa, Katja ^a   Schwarz, Sandra ^a   Hunger, Heike ^a   Schmid, Franziska ^a   Kissling, Werner ^a   Davis, John M ^b   Leucht, Stefan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

akathisia; antiparkinson medication; classification of antipsychotics

Indexed keywords

AMISULPRIDE; ANTIPARKINSON AGENT; ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; ZOTEPINE;

AKATHISIA; ARTICLE; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; META ANALYSIS; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; ENDPOINT DETERMINATION; EXTRAPYRAMIDAL TRACTS; HUMANS; SCHIZOPHRENIA;

EID: 84555186903     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbq042     Document Type: Article

References (43)

1. Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry. 1989;50:329-338. (Pubitemid 19239055)
2. Ereshefsky L,WatanabeMD, Tran-Johnson TK. Clozapine: an atypical antipsychotic agent. Clin Pharmacol. 1989;8:691-709. (Pubitemid 19263882)
3. Barnes TR, McPhillips MA. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int Clin Psychopharmacol. 1998;13(suppl 3):S49-S57. (Pubitemid 28282871)
4. Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry. 1998;59:69-75. (Pubitemid 28141238)
5. Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A, III, Assuncxão-Talbott S. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry. 2009;70:627-643.
6. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31-41.
7. Leucht S, Komossa K, Rummel-Kluge C, et al. A metaanalysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166:152-163.
8. Adams CE, Coutinho E, Davis JM, et al. Cochrane Schizophrenia Group in the Cochrane Library Chichester. Chichester, UK: John Wiley & Sons Ltd; 2006.
9. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5, in The Cochrane Library, Issue 3 Chichester, UK: Wiley & Sons Ltd; 2005.
10. Komossa K, Rummel-Kluge C, Hunger H, et al. Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;1:CD006624.
11. Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. 2010;2:CD006654.
12. Komossa K, Hunger H, Schmidt F, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. 2010;1:CD006625.
13. Komossa K, Hunger H, Schmidt F, Schwarz S, Leucht S, Rummel-Kluge C. Risperidone versus other atypical antipsychotics for schizophrenia (protocol). The Cochrane Library. Chichester, UK: Wiley & Sons Ltd; 2007.
14. Komossa K, Rummel-Kluge C, Hunger H, et al. Zotepine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010; 1:CD006628.
15. Komossa K, Rummel-Kluge C, Hunger H, et al. Sertindole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009;2:CD006752.
16. Komossa K, Rummel-Kluge C, Hunger H, et al. Zotepine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009;4:CD006627.
17. Komossa K, Rummel-Kluge C, Schmid F, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009;4:CD006569.
18. Green S, Higgins JPT. Cochrane Handbook of Interventions. Chichester, UK: Wiley&Sons; 2008.
19. Der-Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188. (Pubitemid 17189972)
20. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry. 2006;7:5-40. (Pubitemid 43878525)
21. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet. 1999;354:1896-1900.
22. Egger M, Davey SG, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997;315:629-634. (Pubitemid 27387172)
23. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58:538-546. (Pubitemid 28100274)
24. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A metaanalysis of placebo-controlled trials. Mol Psychiatry. 2009;14:429-447.
25. De Hert M, Wampers M, van WR, Peuskens J. Anticholinergic use in hospitalised schizophrenic patients in Belgium. Psychiatry Res. 2007;152:165-172. (Pubitemid 47214644)
26. Findling RL, Robb A, Nyilas M, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008;165:1432-1441.
27. Scherk H, Pajonk FG, Leucht S. Second generation antipsychotics in the treatment of acute mania: a systematic review and meta-analysis of randomized, controlled trials. Arch Gen Psychiatry. 2007;64:442-455. (Pubitemid 46556468)
28. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355:1525-1538. (Pubitemid 44547805)
29. Karow A, Czekalla J, Dittmann RW, et al. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry. 2007;68:75-80. (Pubitemid 46220127)
30. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 1997;23:637-651. (Pubitemid 27485972)
31. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(suppl 4):1-46.
32. Van Putten T, May PR. Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Arch Gen Psychiatry. 1978;35:477-480. (Pubitemid 8337039)
33. Gervin M, Browne S, Garavan J, Roe M, Larkin C, O'Callaghan E. Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology. Eur Psychiatry. 1999;14:405-409.
34. Tenback DE, van Harten PN, Slooff CJ, van OJ. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am J Psychiatry. 2006;163:1438-1440. (Pubitemid 44464418)
35. Correll CU, Kane JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with secondgeneration antipsychotics: a systematic review. J Child Adolesc Psychopharmacol. 2007;17:647-656.
36. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of one-year studies. Am J Psychiatry. 2004;161:414-415.
37. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21:151-156. (Pubitemid 351339869)
38. Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal sideeffects of antipsychotics in a randomised trial. Br J Psychiatry. 2008;193:279-288.
39. Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia-a randomized controlled trial. JAMA. 2003;290:2693-2702. (Pubitemid 37475597)
40. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085-1097. (Pubitemid 351418005)
41. Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med. 2009;39:1591-1602.
42. Grunder G, Hippius H, Carlsson A. The 'atypicality' of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov. 2009;8:197-202.
43. Jindal RD, Keshavan MS. Classifying antipsychotic agents: need for new terminology. CNS Drugs. 2008;22:1047-1059.